Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation  by Gidal, Barry E et al.
doi: 10.1053/seiz.1999.0372, available online at http://www.idealibrary.com on
Seizure 2000; 9: 131–136
Efficacy of lamotrigine in institutionalized,
developmentally disabled patients with epilepsy: a
retrospective evaluation
BARRY E. GIDAL∗, JILL KERRICK WALKER†, REX S. LOTT†, RON SHAW‡, JAMES SPETH§,
KATHRYN J. MARTY§ & PAUL RUTECKI¶
∗Associate Professor, University of Wisconsin, School of Pharmacy and Department of Neurology,
425 N. Charter Street, Madison, WI, USA 53706; †Fircrest School, Seattle, WA, USA; ‡Central
Wisconsin Center for Developmentally Disabled, Madison, WI, USA; §School of Pharmacy, University
of Wisconsin, Madison, WI, USA; ¶Associate Professor, Department of Neurology, University of
Wisconsin, Madison, WI, USA
Correspondence to: B. E. Gidal, Pharm. D., University of Wisconsin, School of Pharmacy and Department of Neu-
rology, 425 N. Charter Street, Madison, WI 53706, USA. E-mail: begidal@pharmacy.wisc.edu
The paper evaluates the efficacy of the newer anticonvulsant lamotrigine in a developmentally disabled patient population. A
retrospective evaluation was done at two institutional centres to assess adjunctive lamotrigine (Lamictalr) efficacy in a devel-
opmentally disabled population. Mean seizure frequency was compared between a 2-month pre-lamotrigine baseline period and
a 2-month treatment period. A 3-month lamotrigine titration phase occurred between baseline and treatment periods. Seizure
frequency data was obtained from standardized, daily seizure records. Adverse effect data was obtained from medical and nurs-
ing notes. An intent to treat analysis was performed. Data were analysed using Student’s t-test for paired data. We evaluated
44 centre residents (25 male, 19 female, average age 33 ± 11 years). Mean lamotrigine dose was 272 ± 133 mg per day. A
significant reduction in seizure frequency was noted. Seizure frequency (all seizures) was 10.1±11.2 during the baseline period
vs. 5.8± 7.9 seizures per month during the treatment period (P = 0.002). Thirty-two percent of patients (n = 14) had greater
than a 75% reduction in seizure frequency. Twenty-three percent of patients (n = 10) had a 50–74% seizure reduction. Twenty-
five percent of patients (n = 11) had less than a 50% reduction in seizures, while 20% (n = 9) had an increase in seizures.
A significant reduction of 48% in generalized seizures (9.5 ± 11.6 vs. 4.9 ± 6.5 seizures per month, P = 0.013) was noted.
Reductions in partial seizure frequency of 48% (7.9 ± 10 vs. 4 ± 6.6 seizures per month, P = 0.16) as well as in mixed-type
seizures (19.9 ± 9.3 was vs. 15 ± 12.1 seizures per month, P = 0.11) were also seen; however, these changes did not reach
significance. Overall, lamotrigine was well tolerated by the subject population. Adjunctive treatment with lamotrigine appears
to be an efficacious and well-tolerated treatment for seizures in a significant percentage of developmentally disabled patients
with epilepsy.
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INTRODUCTION
Epilepsy is a common co-morbidity in approximately
20–50% of patients with mental retardation and de-
velopmental disabilities. Epilepsy in these patients
is complex and patients may present with multiple
seizure types including partial, as well as general-
ized seizures1. In addition, many of these patients
have intractable, or incompletely controlled seizures2.
More than 63% of patients in residential care facil-
ities have severe cerebral palsy in addition to men-
tal retardation and epilepsy. These patients may have
sensory impairments, behaviour disturbances, psychi-
atric disorders, and other medical abnormalities3. Pa-
tients with cerebral palsy have a higher incidence of
epilepsy than patients without, and epilepsy is an in-
dicator of cerebral palsy severity. Frequently, seizures
encountered in these patients are intractable to treat-
ment with the older antiepileptic drugs (AEDs). In
addition to seizure intractability to available medi-
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cations, determination of a specific seizure-type di-
agnosis can be difficult, and neurologic impairments
such as mental retardation potentially increases sus-
ceptibility to cognitive adverse effects attributable to
AEDs1. Both mood and behaviour may be worsened
by AEDs in these patients. In this population, poly-
therapy with older AEDs, including barbiturates has
been common4. Pellock and Hunt reported that re-
moval of sedating drugs such as phenobarbital resulted
in decreased sedation, aggression and irritability4.
The ideal AED for the treatment of epilepsy in pa-
tients with developmental handicaps would have ef-
ficacy against both partial and generalized seizures,
minimal adverse cognitive and behavioural effects,
and minimal pharmacokinetic drugs interactions5.
Since 1993, five new AEDs have been introduced to
the US market, and the usage of these drugs instead
of the older antiepileptics is debated6. In particular,
the role of these newer agents in the treatment of re-
fractory seizures in patients with severe developmental
disabilities is still unclear.
Lamotrigine (LTG) is a novel antiepileptic drug that
is indicated for the adjunctive and monotherapy7 treat-
ment of partial seizures with and without secondary
generalization. Lamotrigine is also approved for use
in patients with seizures associated with Lennox–
Gastaut syndrome8, 9. Efficacy in the treatment of ab-
sence seizures has also recently been suggested10. Al-
though the adjunctive use of LTG for refractory partial
seizures has been well established, data regarding the
specific use of LTG in severely retarded, developmen-
tally disabled patients is limited.
Given its favourable cognitive and neurotoxic ad-
verse effect profile, as well as its demonstrated efficacy
as adjunctive treatment for refractory complex-partial
seizures, LTG may be a useful agent in this unique
clinical setting.
The primary objective of the present retrospective
evaluation was to evaluate the efficacy of LTG in de-
velopmentally disabled patients with epilepsy. In addi-
tion, any adverse reactions attributable to LTG admin-
istration and necessitating drug discontinuation were
identified.
MATERIALS AND METHODS
Patients
Medical and pharmacy records were reviewed to iden-
tify all patients who had, or were receiving LTG, dur-
ing the period 1995–1996. All patients having a di-
agnosis of mental retardation (profound mental re-
tardation, IQ < 20), developmental disabilities and
epilepsy, with seizure type documented prior to eval-
uation using ILAE classification11, were included in
this evaluation. Study patients were evaluated in two
clinical sites (Seattle, WA and Madison, WI).
Drug dosage and escalation
Lamotrigine therapy was initiated based upon clinical
indication, and the final drug dosage was at the dis-
cretion of the attending physician. During the period
of study evaluation, LTG serum concentration deter-
minations were not routinely performed. Patients had
no prior exposure to LTG.
Assessment and evaluation
This study was designed to include both retrospective
and concurrent observation, with each patient serving
as their own control. Our review was structured a pri-
ori with respect to outcome measures and time frame.
This evaluation consisted of three phases. Phase 1
consisted of a baseline period of 2-months preceding
LTG initiation. Baseline and on-treatment seizure fre-
quency were recorded daily using a standardized for-
mat by nursing and residential care staff. Phase 2 was
designated as the drug escalation period. Three months
were allowed for LTG dosage escalation. This time pe-
riod was chosen to be consistent with package insert
dosing guidelines. Phase 3 was the treatment observa-
tion period, which corresponded to months 4 and 5 on
medication. The total study evaluation period, there-
fore, was 7 months. The primary outcome measure
for this evaluation was a change in seizure frequency.
The percentage change in seizure frequency was cal-
culated as follows: (treatment period average − base-
line average)/baseline average × 100. Adverse effect
data were obtained from nursing and medical progress
notes. Seizure types were categorized as either gen-
eralized, partial, or mixed. Differences in the seizure
frequency are compared between Phase 1 (baseline pe-
riod) and Phase 3 (treatment period) using the Stu-
dent’s t-test for paired data. Statistical significance
was assigned at a P < 0.05. All data are presented
as mean ± SD. An intent-to-treat analysis was used
in this evaluation. This study was approved by the in-
stitutional review board at each site prior to the study
initiation.
RESULTS
The overall study group (n = 44) consisted of 25 men
and 19 women, with a mean age of 33.5 ± 11 years
(8–59 years). All the patients had profound mental re-
tardation (IQ < 20). The average number of years
since the onset of seizures was 32. Mean LTG dose
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was 272 ± 133 mg per day. Concomitant AEDs in-
cluded carbamazepine (n = 16), phenytoin (n = 14),
phenobarbital (n = 6), primidone (n = 1), val-
proic acid (n = 12), clonazepam (n = 4), ethosux-
imide (n = 2), gabapentin (n = 6), felbamate (n =
1). Between baseline and end-of-treatment evaluation
period, dosages of concomitant AEDs remained un-
changed in 21 patients. Dosages of concomitant AEDs
were reduced in 21 patients (carbamazepine= 10, val-
proic acid = 7, phenytoin = 4), and increased in two
individuals (phenytoin = 2).
Of the overall study group, 24 patients (17 men
and 7 women, 31 ± 12 years, 8–59 years) had gen-
eralized seizures including tonic–clonic, tonic, atonic
and myoclonic seizures. These individuals had symp-
tomatic generalized epilepsies as opposed to idio-
pathic epilepsy. Fifteen patients had partial seizures
(seven men and eight women, 36.3 ± 8.8 years, 22–
53 years old). Five patients (one man and four women,
37.2± 10.3 years, 29–55 years old) were classified as
having a mixed seizure disorder (Fig. 1).
Overall, a seizure frequency reduction of>75% was
seen in 32% (n = 14) of patients (Table 1). A 50–
74% reduction in seizure frequency was seen in 23%
(n = 10). A 25–49% reduction in seizure frequency
was seen in 11% of patients (n = 5). Fourteen percent
of the patients (n = 6) had between zero and 24%
reduction in seizure frequency. Twenty-one percent of
patients were noted to have an increase in seizure fre-
quency. When all seizures are considered, a statisti-
cally significant reduction was noted between base-
line and treatment period (10.2 ± 11.2 vs. 5.8 ± 7.8
seizures per month, P = 0.002).
Table 1: Summary of percentage seizure frequency
reduction.
Seizure frequency N Patients (%)
reduction (%)
>75 14 32
50–74 10 23
25–49 5 11
0–24 6 14
Increased seizure frequency 9 21
Significant reductions of 48% were noted in the fre-
quency of generalized tonic–clonic seizures (9.5±11.6
vs. 4.9 ± 6.5 seizures per month, P = 0.013) (Ta-
ble 2). Although partial seizures were reduced 48%
from baseline (7.9 ± 10 vs. 4.1 ± 6.6 seizures per
month), this change failed to achieve statistical signif-
icance (P = 0.16), perhaps reflecting the relatively
small sample size. Similarly, for mixed-type seizures,
there was a non-significant reduction in seizure fre-
quency (19.9 ± 9.3 vs. 15 ± 12.1 seizures per month,
P = 0.11). Six patients (13%), each of whom had
at least one seizure during baseline, were seizure free
during the treatment evaluation period. No episodes of
status epilepticus occurred during any phase of obser-
vation.
Few treatment-emergent adverse drug effects were
noted. Gastrointestinal symptoms (vomiting) were
noted in two patients, and led to drug discontinuation.
Of the 44 patients evaluated, five were noted to display
self-injurious behaviours at baseline. Following LTG
treatment, three patients displayed an increase in these
behaviours which resulted in discontinuation of LTG.
No serious biochemical abnormalities or rash were
noted. Clinically significant increases or changes in se-
dation were not noted. In general, LTG was well toler-
ated in this population. Overall, treatment was discon-
tinued due to adverse effects in 11% of patients.
DISCUSSION
Our data suggests that LTG may be a useful adjunc-
tive medication in this difficult population, and is in
general agreement with other, albeit limited, experi-
ence. In an early report, Uvebrant and Bauziene de-
scribed their experience with LTG in 45 children with
mental retardation, autism, attention deficit disorder
or other severe neurological or neuropsychiatric im-
pairments12. Concurrent LTG therapy for a mean of
14 months resulted in complete seizure control in 11%
of patients. An additional 36% demonstrated a >30%
reduction in seizure frequency. Seizure control did not
improve in over half the patients studied. The most
common adverse events encountered were sleep dis-
turbance and rash.
King et al.13 conducted a retrospective chart review
of 53 developmentally disabled patients treated with
LTG and reported responder rates in the symptomatic,
mixed, generalized, and difficult to classify seizures
that were comparable to the present study. Overall,
53% of patients demonstrated greater than 50% im-
provement in seizure frequency. Similar to our expe-
rience there were no cases of rash, haematological ef-
fects, nor status epilepticus. Treatment-emergent ad-
verse effects did not lead to drug discontinuation in
any patient.
In a retrospective review of adults with learn-
ing disabilities and refractory seizures, Bhaumik et
al.14 compared the outcome of administration of
three AEDs (LTG, gabapentin and vigabatrin). Effi-
cacy rates were similar between the individual agents.
With respect to LTG, the duration of treatment was
13 months (range 1–36 months). Of the 25 patients
receiving LTG (mean age 36 ± 9 years, 60% severe–
profound MR), 36% of the patients on LTG were
shown to have a greater than 50% seizure reduction in
add-on therapy. None of the patients became seizure-
free. Increased seizure frequency was seen in 24%
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Fig. 1: Patient demographics and seizure type distribution. 1, generalized seizures; 2, partial seizures; 3, mixed-type seizures.
Table 2: Results: Seizure frequency by seizure type (mean ± 1 SD).
Seizure type Baseline Treatment (sz/mo) Change (%)
(seizures per month) (seizures per month)
Overall 10.2± 11.2 5.8± 7.8 −43 (P = 0.002)
Generalized 9.5± 11.6 4.9± 6.5 −48 (P = 0.013)
Partial 7.9± 10 4.1± 6.6 −48 (P = 0.16)
Mixed 19.9± 9.3 15± 12.1 −25 (P = 0.11)
of patients, and the authors note that this may have
been associated with larger doses of LTG. Although
an increase in seizure frequency was noted in a simi-
lar number of patients in the present study (21%); no
relationship to LTG dose was apparent. Twenty-eight
percent of the patients (n = 7) experienced adverse ef-
fects that included rash (n = 2), behaviour problems
(n = 2), persistent vomiting (n = 1), and unsteady
gait (n = 1). Of note, one patient did develop Steven–
Johnson syndrome.
In an open trial15 of 37 mentally retarded children
and adolescents treated with LTG for a median of
7 months, a seizure reduction of between 50 and 100%
was seen in 35% of patients. The authors note that effi-
cacy may have been greater in children suffering from
primary generalized seizures.
Sorensen16 reviewed 200 mentally retarded patients
(n = 54 profound MR) treated with LTG for a mean
duration of 17 ± 2.2 months (range 1–65 months).
Fifty-eight percent of the patients had a greater than
50% improvement in seizure frequency. Twenty-three
percent of the patients were noted to have LTG ther-
apy discontinued due to either lack of efficacy (includ-
ing increased seizures) or adverse effects. Behavioural
and/or psychiatric adverse effects were noted in ap-
proximately 22% of patients. Rash was observed in
5%.
Finally, in an interim analysis of a prospective trial,
McKee et al.17 reported that in 33 mentally retarded
(82% severe–profound MR) patients treated with LTG
for 36 weeks, 36% of patients had a 50% reduction in
seizure frequency. While 15% of patients did become
seizure free, 10–15% of patients showed a worsening
in behaviour and/or functional status.
There are numerous issues involved in the treat-
ment of this particular patient population. These
patients may have multiple physical and psychi-
atric/psychological problems, and may be receiving
multiple medications that potentially result in phar-
macokinetic or pharmacodynamic interactions. In ad-
dition, these patients may continue to have seizures
despite multiple AED combinations. Assessment of
seizure activity, particularly complex-partial seizures,
may be complicated or confused with individual pa-
tient behavioural or psychological symptoms. For sim-
ilar reasons, assessment of drug-related adverse effects
is difficult in this population1. Assessment of potential
drug toxicity is also confounded by the diminished ca-
pacity of these patients to communicate. In general,
LTG was well tolerated and the adverse effects noted
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in our study are consistent with previously published
experience. Interestingly, treatment-emergent rash was
not observed in any patient. Data from clinical trials
and post-marketing surveillance studies suggest that
rash may occur in approximately 10% of adult patients
treated with LTG. Rapid drug escalation and concomi-
tant treatment with valproic acid may increase the like-
lihood of rash18, 19. Conceivably, the slow, judicious
dosage titration rates used in our patients were respon-
sible for the absence of this side-effect.
Adverse events such as increased aggression and
behavioural deterioration may be somewhat unique
to this population. Beran and Gibson20 reported sur-
vey data on behaviour changes during LTG treatment
and found 47.4% of patients exhibited aggressive be-
haviour thought related to LTG. The mean age of these
patients was 33.9 ± 8.91 years. No related aggres-
sion was found in 10 patients (52.6%). This aggres-
sion occurred within 1 month of initiation at low titra-
tion doses. In the present study, five patients displayed
self-injurious behaviours at baseline. After the initia-
tion and titration of LTG, three patients (6.8%) dis-
played an increase in these behaviours requiring dis-
continuation.
As noted previously, aggression and/or adverse be-
havioural changes have been observed by other inves-
tigators. While these behavioural effects certainly do
appear to be associated with LTG in these patients, de-
termining the underlying mechanism(s) of behavioural
changes may not be straight forward. In many cases,
these patients may be non-verbal, and hence, unable
to express their feelings. This is particularly true in the
profoundly impaired patient. Since LTG is frequently
used as adjunctive treatment in these largely refractory
patients, it is conceivable that the occurrence of com-
mon adverse neurosensory effects may be expressed
differently in a non-verbal patient. Besag et al.21 have
recently noted behavioural disturbance as a possible
manifestation of an adverse pharmacodynamic inter-
action between carbamazepine and LTG in a learning-
disabled population. Clearly, these issues merit further
investigation.
CONCLUSION
Our observations suggest that LTG can play a positive
role in the care of these developmentally disabled per-
sons with epilepsy. At present, although a substantial
body of literature exists documenting both the efficacy
and tolerability of LTG in adult ambulatory patients
with partial seizures, little data exist in the profoundly
impaired, institutionalized epilepsy patient. The rela-
tionship between randomized, controlled clinical tri-
als done to secure drug licensing may not reflect ev-
eryday clinical practice, or be generalizable to unique
populations such as ours22. With that in mind, we
must acknowledge possible limitations of the present
study. Although this study was retrospective, several
elements were incorporated into this study design that
lend it strength. Baseline and treatment observation
periods were established a priori, and intent-to-treat
assumption was made prior to data analysis. While
seizure assessment may be problematic in these pa-
tients, both centres involved in this trial used stan-
dardized seizure records that were maintained daily
by trained personnel. Unfortunately, no such standard-
ized, systematic assessment tool for adverse effects
was in use at the time of this evaluation. While nurs-
ing and medical notes were extensive, the potential for
reporting bias does exist.
Clearly, further investigations aimed toward iden-
tifying patient characteristics that may predispose to
untoward adverse behavioural effects would be help-
ful. In addition, further information regarding both
pharmacokinetic as well as pharmacodynamic inter-
actions in this population would be useful. For ex-
ample, the combination of LTG and valproic acid has
been reported to be a particularly useful, possibly syn-
ergistic combination in patients with refractory par-
tial seizures23, 24. Unfortunately, we lacked sufficient
power to discern specific differences in efficacy be-
tween various drug combinations. Data from ongoing,
prospective trials should further clarify these issues.
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